Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Follow-Up Questions
Agenus Inc의 CEO는 누구입니까?
Dr. Garo Armen은 1994부터 회사에 합류한 Agenus Inc의 Chairman of the Board입니다.
AGEN 주식의 가격 성능은 어떻습니까?
AGEN의 현재 가격은 $4.55이며, 전 거래일에 decreased 0% 하였습니다.
Agenus Inc의 주요 사업 주제나 업종은 무엇입니까?
Agenus Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Agenus Inc의 시가총액은 얼마입니까?
Agenus Inc의 현재 시가총액은 $144.9M입니다
Agenus Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Agenus Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 5명의 매수, 2명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
